EE200100134A - Kiiresti vabastav tablett - Google Patents

Kiiresti vabastav tablett

Info

Publication number
EE200100134A
EE200100134A EEP200100134A EEP200100134A EE200100134A EE 200100134 A EE200100134 A EE 200100134A EE P200100134 A EEP200100134 A EE P200100134A EE P200100134 A EEP200100134 A EE P200100134A EE 200100134 A EE200100134 A EE 200100134A
Authority
EE
Estonia
Prior art keywords
quick release
release tablet
tablet
quick
release
Prior art date
Application number
EEP200100134A
Other languages
English (en)
Estonian (et)
Inventor
Forsman Sigbrit
Karlsson Christer
Karlsson Magnus
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200100134A publication Critical patent/EE200100134A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200100134A 1998-09-03 1999-08-27 Kiiresti vabastav tablett EE200100134A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802973A SE9802973D0 (sv) 1998-09-03 1998-09-03 Immediate release tablet
PCT/SE1999/001471 WO2000013671A1 (en) 1998-09-03 1999-08-27 Immediate release tablet

Publications (1)

Publication Number Publication Date
EE200100134A true EE200100134A (et) 2002-06-17

Family

ID=20412467

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100134A EE200100134A (et) 1998-09-03 1999-08-27 Kiiresti vabastav tablett

Country Status (32)

Country Link
US (3) US6521253B1 (is)
EP (2) EP1109537B1 (is)
JP (2) JP4026678B2 (is)
KR (2) KR100696350B1 (is)
CN (3) CN1158070C (is)
AR (1) AR029313A1 (is)
AT (1) ATE286385T1 (is)
AU (1) AU746129B2 (is)
BR (1) BR9913400A (is)
CA (1) CA2341397C (is)
CZ (1) CZ300830B6 (is)
DE (1) DE69923074T2 (is)
EE (1) EE200100134A (is)
ES (1) ES2234296T3 (is)
HU (1) HU227278B1 (is)
ID (1) ID29629A (is)
IL (2) IL141439A0 (is)
IS (1) IS5869A (is)
MY (1) MY124359A (is)
NO (1) NO20011085L (is)
NZ (2) NZ539749A (is)
PL (1) PL195603B1 (is)
PT (1) PT1109537E (is)
RU (2) RU2252751C2 (is)
SA (1) SA99200683B1 (is)
SE (1) SE9802973D0 (is)
SK (1) SK285507B6 (is)
TR (2) TR200100666T2 (is)
TW (1) TW561056B (is)
UA (1) UA75567C2 (is)
WO (1) WO2000013671A1 (is)
ZA (1) ZA200101762B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
NZ540748A (en) * 2000-06-22 2007-04-27 Novartis Ag An oral solid pharmaceutical composition comprising valsartan and a filler in a weight ratio from 2:1 to 1:1
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CN1642546A (zh) * 2002-03-28 2005-07-20 帝人株式会社 含有单一晶型的固体制剂
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
JP5344289B2 (ja) * 2006-06-29 2013-11-20 株式会社ツムラ 漢方エキス含有錠剤組成物
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
WO2008092231A1 (en) 2007-02-01 2008-08-07 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DE102008014237A1 (de) * 2008-03-14 2009-09-17 J. Rettenmaier & Söhne Gmbh + Co. Kg Direktverpressbares Tablettierhilfsmittel
US8513261B2 (en) * 2009-03-13 2013-08-20 Toyama Chemical Co., Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
NZ755378A (en) 2009-03-18 2022-07-29 Resverlogix Corp Novel quinazolinones and related compounds for use as anti-inflammatory agents
KR20190091564A (ko) 2009-04-22 2019-08-06 리스버로직스 코퍼레이션 신규한 소염제
RU2640115C2 (ru) 2011-11-01 2017-12-26 Ресверлоджикс Корп. Фармацевтические композиции замещенных хиназолинонов
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
JO3789B1 (ar) 2015-03-13 2021-01-31 Resverlogix Corp التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601833A (en) 1978-02-06 1981-11-04 Wellcome Found Antacid formulation
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
IT1200178B (it) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US5430023A (en) * 1990-09-28 1995-07-04 Eli Lilly And Company Tripeptide antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
JPH05213927A (ja) * 1992-02-10 1993-08-24 Torii Yakuhin Kk 新規フランカルボン酸アミジノナフチルエステル誘導体およびその酸付加塩
US5532267A (en) 1992-02-10 1996-07-02 Torii & Co., Ltd. Amidinonaphthyl furancarboxylate derivatives and acid addition salts therof
US5470955A (en) 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5436229A (en) * 1994-03-04 1995-07-25 Eli Lilly And Company Bisulfite adducts of arginine aldehydes
CA2193681A1 (en) 1994-07-08 1996-01-25 Astra Aktiebolag New oral pharmaceutical formulation containing magnesium salt of omeprazole
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
TW430561B (en) 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
EP0803251B1 (en) 1996-04-23 2002-07-17 Janssen Pharmaceutica N.V. Immediate release pH-independent solid dosage form of cisapride
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
WO1998011896A1 (en) * 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
CA2239931A1 (en) 1998-07-15 2000-01-15 Bernard Charles Sherman Pharmaceutical tablet comprising norfloxacin
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
EP1165054A4 (en) 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
NO329694B1 (no) 1999-04-13 2010-12-06 Beecham Pharm Pte Ltd Farmasoytisk formulering og anvendelse derav, samt belagt tablett

Also Published As

Publication number Publication date
IL141439A (en) 2006-07-05
TW561056B (en) 2003-11-11
EP1109537B1 (en) 2005-01-05
KR20060097071A (ko) 2006-09-13
JP2002524412A (ja) 2002-08-06
EP1527787A1 (en) 2005-05-04
JP2007039472A (ja) 2007-02-15
IL141439A0 (en) 2002-03-10
CZ2001774A3 (cs) 2001-10-17
HUP0103886A2 (hu) 2002-04-29
ES2234296T3 (es) 2005-06-16
JP4026678B2 (ja) 2007-12-26
RU2005100986A (ru) 2006-06-20
CN1544088A (zh) 2004-11-10
US6521253B1 (en) 2003-02-18
BR9913400A (pt) 2001-05-22
TR200100666T2 (tr) 2001-08-21
IS5869A (is) 2001-02-28
CN1158070C (zh) 2004-07-21
RU2252751C2 (ru) 2005-05-27
ZA200101762B (en) 2002-06-03
CZ300830B6 (cs) 2009-08-19
UA75567C2 (en) 2006-05-15
SA99200683B1 (ar) 2006-12-05
DE69923074T2 (de) 2005-12-08
SE9802973D0 (sv) 1998-09-03
WO2000013671A1 (en) 2000-03-16
CA2341397A1 (en) 2000-03-16
PL195603B1 (pl) 2007-10-31
NZ509943A (en) 2004-01-30
AR029313A1 (es) 2003-06-25
PT1109537E (pt) 2005-04-29
ID29629A (id) 2001-09-06
HUP0103886A3 (en) 2002-08-28
ATE286385T1 (de) 2005-01-15
PL346545A1 (en) 2002-02-11
AU5892499A (en) 2000-03-27
MY124359A (en) 2006-06-30
HU227278B1 (en) 2011-01-28
US20030118644A1 (en) 2003-06-26
CN1951371A (zh) 2007-04-25
CA2341397C (en) 2009-02-03
KR100696350B1 (ko) 2007-03-20
SK285507B6 (sk) 2007-03-01
US20050208128A1 (en) 2005-09-22
SK2812001A3 (en) 2001-09-11
AU746129B2 (en) 2002-04-18
CN1315855A (zh) 2001-10-03
NO20011085D0 (no) 2001-03-02
NO20011085L (no) 2001-05-03
US6875446B2 (en) 2005-04-05
TR200502188T2 (tr) 2006-12-21
EP1109537A1 (en) 2001-06-27
NZ539749A (en) 2006-11-30
KR20010090436A (ko) 2001-10-18
DE69923074D1 (de) 2005-02-10

Similar Documents

Publication Publication Date Title
EE200100134A (et) Kiiresti vabastav tablett
DE60013812D1 (de) Schnellkupplung
DE60038784D1 (de) Schnellkupplung
DE59906289D1 (de) Notbefreiungseinrichtung
NO331255B1 (no) Forlenget frigjoring bukkal bioadhesiv tablett
PT1058538E (pt) Comprimidos de desintegracao rapida
ID23735A (id) Tablet trovafloksasin mesilat
DE69816760D1 (de) Trennfolie
DE69922630D1 (de) Trennfolie
DE50015811D1 (de) Retardersystem
FI981896L (fi) Naulakko
NO993944L (no) Utlösermekanisme
DE60044181D1 (de) Gleitvorrichtung
DE69907022D1 (de) Tablettenspender
DE50015381D1 (de) Retardersystem
EP1074250A4 (en) SUGAR-COATED TABLETS
DE69812401D1 (de) Schnellkupplung
DE69814051D1 (de) Trennmittel
PT879576E (pt) Retrete
FI981576L (fi) Irrokepaperi
DE69717810D1 (de) S1452-tabletten mit schneller freisetzung
ITPR980020A1 (it) Incorniciatura rapida
DE69620917D1 (de) Schnellkupplung
SE9802667D0 (sv) Snabbkoppling
SE9904410D0 (sv) Snabbkoppling